PMN ProMIS Neurosciences Inc.
Company Analysis
Latest News
🟢 ProMIS Neurosciences is trading 5% up today
ProMIS Neurosciences is trading 5.28% up now at $13.76, reversing the 5.19% decline on August 31; no direct catalyst has been identified for the September 1...
🟢 ProMIS Neurosciences is trading 8.51% up in pre-market; no company-specific announcement identified
ProMIS Neurosciences is trading 8.51% up in pre-market at $15.18, after rising from the August 27 close of $13.99; no company-specific announcement dated...
🔴 ProMIS Neurosciences is trading 5.03% down in pre-market with no fresh company-specific announcement
ProMIS Neurosciences is trading 5.03% down in pre-market at $14.16, with no fresh company-specific announcement found for August 21, 2026. - The latest...
🔴 ProMIS Neurosciences is trading 7% down in pre-market amid rising yields, oil and geopolitical tensions
ProMIS Neurosciences is trading 6.82% down now at $13.66 after a weak overnight market backdrop and broader risk-off pressure. - The Nasdaq Composite is down...
ProMIS Neurosciences second quarter 2026 loss of $1.28 beats estimates with zero ARIA-E cases
ProMIS Neurosciences reported a second quarter 2026 net loss that narrowed on a per-share basis compared to the previous year, outperforming analyst...
🔴 ProMIS Neurosciences is trading 5.6% down today; catalyst unclear
ProMIS Neurosciences is trading 5.6% down at $14.13, despite the broader market moving higher on August 12, 2026; no clear company-specific announcement...
ProMIS Neurosciences Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 13, 2026
ProMIS Neurosciences is expected to report a Q2 2026 loss of $1.38 per share on zero revenue, with its stock currently trading near $14.72 against an average...
🟢 ProMIS Neurosciences is trading 7% up today as weak payrolls boost rate-cut hopes
ProMIS Neurosciences is trading at $14.32, up 7.43%, as unexpectedly weak July payrolls increased expectations for Federal Reserve rate cuts, favoring...
🔴 ProMIS Neurosciences is trading 5.7% down today after reports of Janus Henderson's Q1 stake acquisition and prior earnings miss.
ProMIS Neurosciences is trading at $13.34 (5.7% down) today. • The decline follows fresh reports of Janus Henderson Group PLC acquiring a 14.41% stake in the...
🟢 ProMIS Neurosciences is trading 5% up today in a technical rebound following recent profit-taking
ProMIS Neurosciences is trading at $14.42 (up 5%) in what appears to be a continuation of a technical rebound following sharp recent swings and...
🟢 ProMIS Neurosciences is trading 15% up today in a technical rebound after recent volatility
ProMIS Neurosciences is trading 15% up at $15.78 in pre-market, extending a sharp rebound after recent volatility and profit-taking. - The move follows prior...
🟢 ProMIS Neurosciences is trading 7.6% up today in a technical rebound from recent weakness
ProMIS Neurosciences is trading at $14.76 (up 7.6%) in pre-market action, rebounding from a period of profit-taking and broader biotech sector weakness seen on...
🔴 ProMIS Neurosciences is trading 5.1% down today on profit-taking and biotech sector weakness
ProMIS Neurosciences is trading 5.1% down at $14.16 as investors lock in gains following a sharp multi-day rally and a broader decline in the biotech...
🟢 ProMIS Neurosciences is trading 7% up today amid a broad risk-on rally in U.S. equities
ProMIS Neurosciences is trading 7% up today at $15.05 as the stock rebounds from recent volatility and follows a broad risk-on rally in U.S. equities. • The...
🟢 ProMIS Neurosciences is trading 6.7% up today as it rebounds amid improving broader risk sentiment
ProMIS Neurosciences is trading at $15.00 (6.7%) up today, rebounding from recent volatility and a sharp gain on July 28 despite a lack of fresh...
🟢 ProMIS Neurosciences is trading 12.8% up today on favorable interim Phase 1b data for Alzheimer’s drug PMN310
ProMIS Neurosciences is trading 12.8% up now at $12.88 after releasing favorable six-month interim data from its PRECISE-AD Phase 1b trial of Alzheimer’s drug...
ProMIS Neurosciences Reports Favorable Interim Phase 1b Data for Alzheimer's Drug PMN310
ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker data from its PRECISE-AD Phase 1b clinical trial evaluating PMN310 in...
🟢 ProMIS Neurosciences is trading 15.8% up today after bullish analyst coverage and upcoming webinar on clinical trial data
• Chardan initiated coverage with a Buy rating and a $20 price target on July 27, sparking investor interest. • The company is also set to host a webinar...
ProMIS Neurosciences Surges 12.7% on Chardan's Buy Call — But Can a Micro-Cap Biotech With No Revenue Justify a $20 Target?
Shares of ProMIS Neurosciences jumped 12.7% to $13.21 after Chardan initiated coverage with a Buy rating and a $20 price target, snapping a brutal five-session...
🟢 ProMIS Neurosciences is trading 12.7% up today after Chardan initiated coverage with a Buy rating and $20 price target
ProMIS Neurosciences is trading 12.7% up at $13.21 following a sharp after-hours relief bounce triggered by a Buy rating initiation from Chardan. • Chardan...